Frazer Supply Brigatinib Anti-Cancer API CAS 1197953-54-0

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Brigatinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• CAS No: 1197953-54-0
• Shelf Life: 2 Years
• Test Method: HPLC
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Delivery Time: 7-10days
• Mf: C29h39cln7o2p
• MW: 584.092421
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2500kg/Month

Product Description

Raw Material Brigatinib Ap26113 Anti-Cancer API CAS 1197953-54-0

Specification of Analysis

Item	Test Standard		Testing Result
Purity	98%
THC	Not detected		Undetected
Assay	Method HPLC calculated on the anhydrous basis limit of quotation (LOQ) 0.8ppm
Appearance	White powder		White  powder
Identification	In the recorded chromatograms under the determination of the substance, retention time of the main peak of the solution should be consistent with the retention of time of the main peak of the reference solution		Complies
Melting Point	65~66ºC		65.5ºC
Loss on Drying	NMT 1.0%		0.21%
Residual solvents	Ethanol NMT 400ppm Heptane NMT 400ppm		1.92ppm 256.0ppm
Heavy Mental	NMT 20ppm		Complies
Microbial Limite Test	Method: Plate Counting
Total aerobic bacteria count	NMT 1000cfu/g		Complies
Combined molds and yeast	NMT 100cfu/g		Complies
E. Coli	Not detacted per gram		Complies
Salmanella	Not detacted per 10 gram		Complies
Conclusion: Conform the testing result is qualified

What is Lidocaine?

Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the in sulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.

Function & Application

Brigatinib, also known as AP-26113, is an orally active, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the in sulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.